Financial

Sanofi braces for patent cliff impact

Matthew Arnold February 09, 2012

Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.

J&J sales up, but earnings wiped out by settlements, product liability and recall costs

Matthew Arnold January 24, 2012

Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.

Prolia, Xgeva fall short of analysts' Q3 sales forecasts

Marc Iskowitz October 24, 2011

Amgen's global sales, up 3% in the third quarter, met analyst estimates, but its new denosumab franchise reflected slower growth than expected.

Company news: Johnson & Johnson, Forest Labs and Berkery Noyes

October 18, 2011

Johnson & Johnson and Forest Labs both posted lower profit for the three months ended September 30.

UK PR pitch could portend US acquisitions for AstraZeneca

Matthew Arnold June 14, 2011

AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.

Which Pfizer brands could stay, go in a sell-off

Marc Iskowitz March 15, 2011

Pfizer may be headed toward a major restructuring that could include the sale of some of its most enduring brands, an analyst says.

Merck, GlaxoSmithKline earnings reflect product difficulties

Ben Comer February 03, 2011

Fourth quarter and full year earnings were posted by Merck and GSK today, and both companies suffered financial losses due to patent expiries, drug safety issues and ongoing litigation.

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.